Gain Therapeutics
Business Services · Maryland, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
4800 Hampden Ln Ste 200, Bethesda, Maryl...Phone Number
(301) 500-1556Website
www.gaintherapeutics.comRevenue
-Stock Symbol
GANXIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
2
2
1
1
1
1
About Gain Therapeutics
Gain Therapeutics is a biotechnology company founded in 2017 that operates at the intersection of technology and healthcare. The company specializes in drug discovery through its proprietary SEE-Tx target identification platform. This innovative technology identifies and optimizes previously untargeted allosteric binding sites, enabling the development of new treatment options for disorders characterized by protein misfolding. Gain Therapeutics has received recognition and funding from prominent research foundations focused on Parkinson's disease and operates internationally with presence in both North America and Europe. The company is publicly traded and continues to advance its research and development efforts in creating novel therapeutic approaches for challenging medical conditions.Explore more
Gain Therapeutics Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Gain Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Check if Gain Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Gain Therapeutics recently announced quarterly report
Funding: Get notified immidiatlly once Gain Therapeutics has new funding data
Product Launch: Get notified when Gain Therapeutics launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Gain Therapeutics is spiking on competitors!
Gain Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Gain Therapeutics
Click to see if Gain Therapeutics had a recent Job posting/layoffs
Recommended Actions
Reach out to Masked Content who joined Gain Therapeutics as Masked Content
Find more new buyers
Compare Similar Companies to Gain Therapeutics
Compare insights from companies similar to Gain Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Gain Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Gain Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Gain Therapeutics.
Gain Therapeutics Tech Stack
A closer look at the technologies used by Gain Therapeutics
Most Recent Scoops
Person-Based
Project
Gain Therapeutics has reported that at the 150-day follow-up in its GT-02287 clinical program, treatment benefit on the UPDRS scale was maintained at approximately 3 points, with an estimated 6-point gap relative to untreated patients a range considered clinically meaningful.
Medical Research, Pharmaceuticals, Clinical Operations
Project
Gain Therapeutics has reported that a side-by-side analysis with Bial's discontinued GCase activator which failed to demonstrate efficacy in a Phase II study indicated that Bial's compound achieved lysosomal improvements but lacked neuroprotection in other cellular compartments, a limitation not observed with GT-02287.
Pharmaceuticals
Project
Gain Therapeutics has reported anecdotal improvements across multiple study centers in Australia among patients treated with GT-02287, including return of taste and smell, improved gait, and improved concentration, with the recovery of smell noted as clinically significant given its established role as an early predictor of worse cognitive outcomes in Parkinson's disease.
Medical Research
Project
Gain Therapeutics News & Media
Gain Therapeutics Receives FDA Clearance of IND to Advance GT-02287 into Phase 2 Clinical Development for Parkinson’s Disease
IND authorization paves the way for initiation of GT-02287 Phase 2 clinical development in the U.S., expected during 3Q26Gain Therapeutics to Present at H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit
BETHESDA, Md., June 10, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that Gene Mack, President and CEO, will participate in a virtual fireside chat and one-on-one meetings at the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit, being held in a hybrid format from June 15-16, 2026.Gain Therapeutics expands ‘compelling’ evidence base for Parkinson’s candidate
Gain Therapeutics’ Parkinson’s candidate GT-02287 showed durable clinical stability and biomarker improvements in extended Phase 1b data.Gain Therapeutics Presents Positive Interim Data from Phase 1b Clinical Study of GT-02287 at 3rd International GBA1 Meeting 2026
MDS-UPDRS scores remained stable and durable across overall study population after 150 days of treatment with GT-02287
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Frequently Asked Questions Regarding Gain Therapeutics
Sign Up For FreeTo access detailed company insights
Gain Therapeutics is a biotechnology company founded in 2017 that operates at the intersection of technology and healthcare. The company specializes in drug discovery through its proprietary SEE-Tx target identification platform. This innovative technology identifies and optimizes previously untargeted allosteric binding sites, enabling the develop... Read More
